P-003. Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir±Ribavirin treatment in HCV infected chronic hemodialysis patients: A single center experience

摘要

The prevelance of HCV in Turkey is 0.5–1.0%. According to Turkish Society of Nephrology registry, anti-HCV positivity rate was 6.94% in chronic hemodialysis patients in 2013. Beyond the liver-related mortality, HCV infection increases all kind of mortality in hemodialysis patients. In order to decrease the mortality and to eliminate the source of infection, hepatitis C must be treated in patients undergoing hemodialysis. Interferon based therapies were cumbersome and less effective in these patients, however DAAs seem highly effective and safe in patients with chronic renal failure. In this study we presented our experiences with Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD) regime in patients undergoing hemodialysis.